본문 바로가기

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3
저널
JOURNAL OF KOREAN MEDICAL SCIENCE24(3) · pp.498 · 2009
피인용
Web of Science 22KCI 0
JCR IF
JCR 2008 0.843
ISSN
1011-8934

저자

  1. 이세련전남대학교
  2. 양덕환전남대학교
  3. 안재숙전남대학교
  4. 김여경전남대학교
  5. 이제중전남대학교
  6. 최영진부산대학교
  7. 신호진부산대학교
  8. 정주섭부산대학교
  9. 조윤영경북대학교
  10. 김종광경북대학교
  11. 손상균경북대학교
  12. 김형준전남대학교
  13. 채이수경북대학교

초록

A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m(2), days 1-5), cytarabine (2.0 g/m(2), days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (>= 500/mu L)and platelets (>= 20,000/mu L) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.

식별자

WoS UID
000267343400023
KCI
ART001348685